IAVI Policy Brief Examines HIV Vaccine Funding

A new policy brief from the International AIDS Vaccine Initiative (IAVI) “summarizes data on HIV vaccine R&D funding trends originally published by the HIV Vaccines and Microbicides Resource Tracking Working Group in 2011,” according to the IAVI website. “The crucial addition of a preventive HIV vaccine to [a comprehensive biomedical HIV prevention] toolkit will not only depend on the sustained commitment of current donors. It will also depend on the support of a diversified field of new champions willing to fund the research required to capitalize on new discoveries in the HIV vaccine field,” the brief states, noting that “[b]etween 2009 and 2010, overall investment in HIV vaccine R&D dropped one percent from $868 million to $859 million” (November 2011).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.